Lv2
105 积分 2021-08-11 加入
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
1小时前
待确认
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial
12天前
已完结
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2个月前
已完结
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2个月前
已完结
Identifying modifiable factors and their joint effect on dementia risk in the UK Biobank
2个月前
已完结
Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis
6个月前
已完结
Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients
7个月前
已完结
UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice
7个月前
已完结
Dutch pharmacogenetics working group (DPWG) guideline for the gene–drug interaction between UGT1A1 and irinotecan
7个月前
已完结
Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management
7个月前
已完结
皖公网安备34019202002308
